Table of Contents
ISRN Oncology
Volume 2011 (2011), Article ID 526384, 6 pages
http://dx.doi.org/10.5402/2011/526384
Research Article

Morbidity and Mortality of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: National Cancer Institute, Mexico City, Mexico

1Department of Surgical Oncology, National Cancer Institute, San Fernando No. 22 Colonia Seccion XVI, Tlalpan, 14080 Mexico City, DF, Mexico
2Department of Medical Oncology, National Cancer Institute, San Fernando No. 22 Colonia Seccion XVI, Tlalpan, 14080 Mexico City, DF, Mexico
3Department of Critical Care Medicine, National Cancer Institute, San Fernando No. 22 Colonia Seccion XVI, Tlalpan, 14080 Mexico City, DF, Mexico

Received 23 May 2011; Accepted 20 June 2011

Academic Editors: T. S. Ganesan and F. Kuhnel

Copyright © 2011 Horacio N. López-Basave et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Peritoneal carcinomatosis (PC) is generally considered a lethal disease, with a poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a new approach for peritoneal surface disease. This study investigated the early experience with this combined modality treatment at a single institute. From January 2007 to March 2010, 24 patients were treated After aggressive CS, with HIPEC (cisplatin 25 mg/m2/L and mitomycin C 3.3 mg/m2/L was administered for 90-minutes at 40.5° C). These data suggest that aggressive CRS with HIPEC for the treatment of PC may result in low mortality and acceptable morbidity. Rigorous patient selection, appropriate and prudent operative procedures were associated with encouraging results in our experience.